Valuation dashboard for Incyte Corporation (INCY) with P/E 15.34, P/B 3.94, EV/EBITDA 9.23 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive a...
Analysis Summary
Incyte Corporation reported revenue of $5.14B in the most recent fiscal year, growing at a 5-year CAGR of 14.0%.
Trailing-twelve-month margins: gross margin 92.6%, operating margin 31.6%, net margin 27.7%.
At the current price of $121.47, INCY trades at a P/E of 15.34 and an ROE of 24.90%. Market capitalisation stands at $24.6B, placing it among large-cap names.
Balance sheet quality for INCY: current ratio of 3.3. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 15.34 |
| Price / Book | 3.94 |
| EV / EBITDA | 9.23 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $110.61 |
| vs Current Price | -8.9% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| INCY | Incyte Corporation | $24.6B | 15.34 | 3.94 | 24.9% |
| BIIB | Biogen Inc. | $31.9B | 37.86 | 1.69 | 4.5% |
| UTHR | United Therapeutics Corporation | $21.2B | 16.49 | 3.32 | |
| RPRX | Royalty Pharma plc | $26.0B | 24.39 | 3.83 | |
| ILMN | Illumina, Inc. | $34.6B | 45.56 | 13.12 | 31.1% |
| GMAB | Genmab A/S | $21.1B | 26.82 | 3.53 | 16.5% |
| DGX | Quest Diagnostics Incorporated | $26.2B | 25.90 | 3.62 | |
| WAT | Waters Corporation | $29.9B | 103.75 | 2.70 | 1.9% |
Price
| Price | $121.47 |
| Market Cap | $24.6B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 24.90% |
| Return on Invested Capital | 20.58% |
| Return on Assets | 18.49% |
| Gross Margin | 92.62% |
| Operating Margin | 31.57% |
| Net Margin | 27.71% |
Related companies: BIIB · DGX · GMAB · ILMN · RPRX · THC · UTHR
Explore sector: Healthcare · Biotechnology
More sections of INCY: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks